PharmiWeb.com - Global Pharma News & Resources
17-Jul-2019

Antibiotic Resistance Market Will Grow 5.5% to a Record $ 12.11 Billion by 2026

The Global Antibiotic Resistance Market Size projected to register USD 12.11 billion by 2026, registering at a CAGR growth of 5.5% over the forecast period 2019 to 2026. Emergence of multi-drug resistant pathogens, growing need to prevent antibiotic effects and rise in incidences of chronic and infectious diseases across the globe have increased the growth of the global antibiotic resistance market. The market in the North America is likely to expand at significant CAGR due to numerous clinical innovations and presence of large number of pharmaceutical companies in the region.

Growing need for antibiotic resistance in cUTI diseases to drive the market growth

Based on disease type, the global antibiotic resistance market is segmented into complicated urinary tract infection (cUTI), complicated intra-abdominal infections (cIAI), blood stream infections (BSI), clostridium difficile infections (CDI), acute bacterial skin and skin structure infections (ABSSSI), hospital acquired, bacterial pneumonia/ventilator (HABP/VABP), community acquired bacterial pneumonia (CABP). Complicated Urinary Tract Infection (cUTI) segment accumulated highest market share in 2017 and expected to grow at highest CAGR throughout the forecast period owing to the high cost of treatment and limited treatment alternatives for gram-negative pathogens which causes majority of infections.

On the other hand, gram-negative pathogens restricts the recently authorized advanced therapies such as Merckrsquo;s Zerbaxa, Allerganrsquo;s Avycaz and Vabomere, due to lack of low cost treatment options. In August 2017, The Medicines Company announced the approval for ldquo;VABOMERErdquo; from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients having complicated urinary tract infections. Antibiotic-resistant gram-positive bacteria causes larger number of infections, thereby increasing the growth of the cUTI segment. However, owing to the availability of various treatment options, the overall cost of gram-positive therapy remains lower as compared to the gram-negative therapy. ABSSSI segment is also projected to show considerable growth during the forecast period.

Download Free Report Sample Pages at https://www.acumenresearchandconsulting.com/request-sample/933

Numerous drug launches is expected to fuel the antibiotic resistance market growth

Antibiotic resistance is a growing public health concern. The growth in antibiotic drugs launches in developing countries is boosting the antibiotic resistance market. Increasing percentage of bacterial infections have led to launch of various antibiotic drugs, thereby propelling the growth of the market globally. Growing need to reduce or eliminate the effectiveness of antibiotics is boosting the demand for antibiotic drugs. Various governments are taking initiatives towards introducing clinically advanced antibiotic drugs in order to overcome the bacterial infections or diseases. For instance, the Food and Drug Administration (FDA) launched several initiatives such as drug labeling regulations, emphasizing the prudent use of antibiotics to address infectious diseases. On the other hand, with increased attention through various public health campaigns, people are becoming aware about the overuse of antibiotics.

Presence of large number of pharmaceutical companies and growing clinical advancements in North America to create more opportunities in the market

Geographically, the global antibiotic resistance market has been divided into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2017, North America accumulated the highest market share in 2017. This is mainly attributed to introduction of numerous antibiotic drugs and presence of large number of market players in the region. North America is anticipated to grow at significant CAGR over the forecast period. Factors such as clinical innovations and high treatment cost are supplementing the growth of the regional market. Prominent players from the region are making considerable investments in drug discovery, resulting in the growth of the market. Asia Pacific is also expected to grow at significant rate during the forecast period owing to the prevalence of various infectious diseases and increase in population.

The Medicines Company, Melinta Therapeutics, Allergan and Tetraphase Pharmaceuticals are likely to continue to lead the global antibiotic resistance market

The company profiling of key players in the global antibiotic resistance market includes company overview, major business strategies and revenues. The key players of the market are TPfizer, Merck, Allergan, The Medicines Company, Melinta Therapeutics, Phage Technologies S.A, Tetraphase Pharmaceuticals, Nabriva Therapeutics. Macrolide Pharmaceuticals, Nemesis Bioscience, Westway Health, AmpliPhi Biosciences and BioVersys GmbH. Industry participant battle on the basis of price, new innovated product launch, and expanding market presence.

VIEW FULL REPORT: https://www.acumenresearchandconsulting.com/antibiotic-resistance-market

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Antibiotic Resistance
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Antibiotic Resistance Market By Disease
1.2.2.1. Global Antibiotic Resistance Market Revenue and Growth Rate Comparison By Disease (2015-2026)
1.2.2.2. Global Antibiotic Resistance Market Revenue Share By Disease in 2017
1.2.2.3. Complicated Urinary Tract Infection (cUTI)
1.2.2.4. Complicated Intra-Abdominal Infections (cIAI)
1.2.2.5. Blood Stream Infections (BSI)
1.2.2.6. Clostridium difficile infections (CDI)
1.2.2.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
1.2.2.8. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
1.2.2.9. Community Acquired Bacterial Pneumonia (CABP)
1.2.2.10. Others
1.2.3. Antibiotic Resistance Market By Pathogen
1.2.3.1. Global Antibiotic Resistance Market Revenue and Growth Rate Comparison By Pathogen (2015-2026)
1.2.3.2. Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)
1.2.3.3. Pseudomonas aeruginosa (Carbapenem-Resistant)
1.2.3.4. Staphylococcus Aureus (Methicillin-Resistant)
1.2.3.5. E. coli/K. pneumoniae (Carbapenem-Resistant)
1.2.3.6. Streptococcus pneumoniae (Penicillin-Non-Susceptible)
1.2.3.7. Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
1.2.3.8. Enterococcus faecium (Vancomycin-Resistant)
1.2.3.9. Haemophilus Influenzae (Ampicillin-Resistant)
1.2.3.10. Others
1.2.4. Antibiotic Resistance Market By Drug Class
1.2.4.1. Global Antibiotic Resistance Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.4.3. Lipoglycopeptides
1.2.4.4. Tetracyclines
1.2.4.5. Cephalosporins
1.2.4.6. Combination therapies
1.2.4.7. Others
1.2.5. Antibiotic Resistance Market by Geography
1.2.5.1. Global Antibiotic Resistance Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Lipoglycopeptides Production Date of Global Antibiotic Resistance Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Antibiotic Resistance Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global Antibiotic Resistance Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Antibiotic Resistance Major Manufacturers in 2017

CHAPTER 4. ANTIBIOTIC RESISTANCE MARKET BY DISEASE

4.1. Global Antibiotic Resistance Revenue By Disease
4.2. Complicated Urinary Tract Infection (cUTI)
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Complicated Intra-Abdominal Infections (cIAI)
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Blood Stream Infections (BSI)
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Clostridium difficile infections (CDI)
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.8. Community Acquired Bacterial Pneumonia (CABP)
4.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.9. Other
4.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. ANTIBIOTIC RESISTANCE MARKET BY PATHOGEN

5.1. Global Antibiotic Resistance Revenue By Pathogen
5.2. Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Pseudomonas aeruginosa (Carbapenem-Resistant)
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Staphylococcus Aureus (Methicillin-Resistant)
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. E. coli/K. pneumoniae (Carbapenem-Resistant)
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Streptococcus pneumoniae (Penicillin-Non-Susceptible)
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.7. Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
5.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.8. Enterococcus faecium (Vancomycin-Resistant)
5.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.9. Haemophilus Influenzae (Ampicillin-Resistant)
5.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.10. Others
5.10.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.10.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. ANTIBIOTIC RESISTANCE MARKET BY DRUG CLASS

6.1. Global Antibiotic Resistance Revenue By Drug Class
6.2. Oxazolidinones
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Lipoglycopeptides
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Tetracyclines
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Cephalosporins
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.6. Combination therapies
6.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.7. Others
6.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET BY COUNTRY

7.1. North America Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Antibiotic Resistance Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. U.S.
7.3.1. U.S. Antibiotic Resistance Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE ANTIBIOTIC RESISTANCE MARKET BY COUNTRY

8.1. Europe Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Antibiotic Resistance Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET BY COUNTRY

9.1. Asia-Pacific Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Antibiotic Resistance Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET BY COUNTRY

10.1. Latin America Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Antibiotic Resistance Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET BY COUNTRY

11.1. Middle East Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Antibiotic Resistance Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA ANTIBIOTIC RESISTANCE MARKET BY COUNTRY

12.1. Africa Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Antibiotic Resistance Market Revenue Share Comparison, 2015 amp; 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. TPfizer
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Merck
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Allergan
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. The Medicines Company
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Melinta Therapeutics
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Phage Technologies S.A
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Tetraphase Pharmaceuticals
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Nabriva Therapeutics
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Macrolide Pharmaceuticals
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Nemesis Bioscience
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies
13.11. Westway Health
13.11.1. Company Snapshot
13.11.2. Overview
13.11.3. Financial Overview
13.11.4. Type Portfolio
13.11.5. Key Developments
13.11.6. Strategies
13.12. AmpliPhi Biosciences
13.12.1. Company Snapshot
13.12.2. Overview
13.12.3. Financial Overview
13.12.4. Type Portfolio
13.12.5. Key Developments
13.12.6. Strategies
13.13. BioVersys GmbH
13.13.1. Company Snapshot
13.13.2. Overview
13.13.3. Financial Overview
13.13.4. Type Portfolio
13.13.5. Key Developments
13.13.6. Strategies
13.14. Others
13.14.1. Company Snapshot
13.14.2. Overview
13.14.3. Financial Overview
13.14.4. Type Portfolio
13.14.5. Key Developments
13.14.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

INQUIRY BEFORE BUYING: https://www.acumenresearchandconsulting.com/inquiry-before-buying/933

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report at https://www.acumenresearchandconsulting.com/buy-now/0/933

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 17-Jul-2019